Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085684 | 0.87 | PTPN1 (0.47) | PTPN1SIRT2FFAR1VDRPPARD | |
| SCHEMBL2086697 | 0.83 | CYP17A1 (0.46) | PTPN1SIRT2FFAR1FFAR4VDR | |
| SCHEMBL2085769 | 0.81 | PTPN1 (0.43) | PTPN1SIRT2FFAR1VDRPPARD | |
| SCHEMBL2771128 | 0.80 | FFAR1 (0.50) | PTPN1SIRT2FFAR1FFAR4CNR2 | |
| SCHEMBL21475912 | 0.78 | HTR7 (0.58) | PTPN1SIRT2FFAR1FFAR4 | |
| SCHEMBL25146605 | 0.77 | RARB (0.48) | PTPN1FFAR1 | |
| SCHEMBL2500558 | 0.77 | FFAR1 (0.55) | FFAR1FFAR4VDRPPARD | |
| SCHEMBL2083064 | 0.75 | CYP4F2 (0.54) | FFAR1SYK | |
| SCHEMBL8969138 | 0.74 | NPC1 (0.49) | PTPN1SIRT2FFAR1FFAR4 | |
| SCHEMBL5105283 | 0.73 | FFAR1 (0.67) | FFAR1FFAR4VDRPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863332-B2 | Biaromatic compound activators of PPARγ receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-04 | — | — | US | disclosed |
| EP-1781297-B1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-10-15 | — | — | EP | disclosed |
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-13 | — | — | US | disclosed |
| EP-1781297-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018326-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | PTPN1 1201/4885SIRT2 826/4885FFAR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.